
Celldex Therapeutics (CLDX) Stock Forecast & Price Target
Celldex Therapeutics (CLDX) Analyst Ratings
Bulls say
Celldex Therapeutics Inc. has demonstrated significant progress in clinical trials, with up to 82% of patients reporting well-controlled or completely controlled chronic spontaneous urticaria, alongside a 95% improvement in quality of life metrics. The company ended the year with a robust financial position, holding $725.3 million in cash, which management anticipates will sustain operations through 2027. Furthermore, the advancement of barzolvolimab across multiple indications reinforces the company's commitment to enhancing patient health outcomes, evidenced by sustained improvements in sleep quality, social functioning, and overall mental health for affected individuals.
Bears say
The negative outlook for Celldex Therapeutics Inc. is primarily driven by the potential risks associated with failed or inconclusive clinical trials, which can significantly impact the company's progress and viability. Additionally, the company's ability to secure adequate funding is crucial to advancing its therapeutics through the development pathway, and any shortfall in this area could hinder its operational capabilities. The substantial unmet need in the treatment of various cancers, highlighted by the current two-thirds of patients not achieving complete control with existing therapies, underscores the high stakes in the company's development efforts, further amplifying the risks involved.
This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Celldex Therapeutics (CLDX) Analyst Forecast & Price Prediction
Start investing in Celldex Therapeutics (CLDX)
Order type
Buy in
Order amount
Est. shares
0 shares